All the Drug Class Drugs
Bruton’s Tyrosine Kinase Inhibitor. acalabrutinib 100 mg. FC tab 60 X 100mg
For pts. with MCL, CLL, or SLL.
As monother. or in combin. with other medicinal prod., 100 mg acalabrutinib 2/d. (equiv. to daily dose of 200 mg.) until dis. progr. or unacceptable tox.
Tmt. of adult pts. with mantle cell lymphoma (MCL) who have received at least one prior ther. Tmt. of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). In combin. with bendamustine and rituximab for tmt. of adult pts. with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplant. (HSCT). Tmt. previously untreated chronic lymphocytic leukemia in combin. with venetoclax with or w/o obinutuzumab.
C/I: Hypersens.
Bruton’s Tyrosine Kinase Inhibitor. Ibrutinib 140 mg. ORAL CAPS: 90, 120.
MCL: 560 mg (4× 140 mg caps.)×1/d.
CLL: 420 mg (3 ×140 mg caps.)×1/d.
Tmt. of adult pts. with (MCL) who have
received at least one prior ther.
This indication is based on overall
response rate.
An improv. in survival, dis.-related symp.
has not been established.
Tmt. of pts. with (CLL) who have received
at least one prior ther.
This indicat. is based on overall response
rate.
An improv. in survival, dis.-related symp.
has not been established.
C/I: None.
